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Vascular calcification is a hallmark of type 2 diabetes. Glucose stimulates calcification in culture of
vascular smoothmuscle cells (VSMCs) but the underlying mechanisms remain obscure. We observed
that high glucose levels stimulated mouse and human VSMC trans-differentiation into chondro-
cytes, with increased levels of Sox9, type II collagen, glycosaminoglycan and Runx2 expression,
and increased alkaline phosphatase activity and mineralization. These effects were associated with
increased expression of IL-1b, which stimulated alkaline phosphatase and calcification, suggesting
that glucose induces chondrocyte differentiation of VSMCs, possibly through IL-1b activation.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Medial arterial calcification is a feature of diabetic individuals.
In 4553 subjects examined in a 20-year longitudinal study, calcifi-
cation was shown to first appear in the feet and develop proximally
[1]. It is believed to be an independent predictor of cardiovascular
abnormalities in diabetic patients and is associated with trophic
foot ulceration and peripheral artery occlusive disease [2–4]. For
instance, in a study of 1059 patients with type 2 diabetes mellitus
(T2DM), vascular calcification, especially in the media, was found to
be a strong independent predictor of total cardiovascular and coro-
nary heart disease mortality, as well as significant predictor of
future coronary heart disease events, stroke, and lower limb ampu-
tation [2]. Moreover, patients with diabetes tend to have more
atherosclerotic plaques than patients without diabetes, notably
more calcified plaques [5,6], and are significantly more likely to
develop coronary heart disease [1,7,8]. Measurement of coronary
artery calcium has recently been considered helpful for cardiovas-
cular risk assessment in asymptomatic adults with diabetes [9].Recent studies have demonstrated that vascular calcification is
an active and tightly regulated biological process with features of
physiological ossification, including trans-differentiation of
VSMCs into cells resembling osteoblasts and/or growth plate chon-
drocytes. Osteoblasts differentiate under the control of the tran-
scription factor Runx2, which stimulates the expression of a type
I collagen rich matrix [10]. Once being differentiated, they express
tissue-nonspecific alkaline phosphatase (TNAP), which allows col-
lagen mineralization by hydrolyzing the mineralization inhibitor
inorganic pyrophosphate [11,12]. Finally, more mature osteoblasts
secrete osteocalcin, a hormone involved in regulating insulin levels
and sensitivity [13]. On the other hand, differentiating chondro-
cytes express the transcription factor Sox9, which drives the pro-
duction of an extracellular matrix (ECM) enriched in collagen
type II, IX and XI, and in sulfated glycosaminoglycans (sGAGs)
[14]. Chondrocytes can further differentiate and become hyper-
trophic, upon expressing Runx2, collagen type X and TNAP, and
they eventually calcify their ECM. During bone development and
repair, two types of bone formation can be encountered: membra-
nous ossification, which is directly formed by the sole action of
osteoblasts, and endochondral ossification, which is governed by
the formation of a calcified template, subsequently replaced by
bone. Depending on the disease, location, species and animal
model, it has always been difficult to distinguish the type of
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membranous and endochondral ossification might occur in some
cases [15]. Accordingly, the term ‘‘osteochondrocyte-like differen-
tiation” of VSMCs has been often used in the literature. However,
if one aims at blocking VSMC trans-differentiation to prevent vas-
cular calcification, it is crucial to undoubtedly discriminate osteo-
blast from chondrocyte differentiation in arteries. Indeed,
chondrocyte and osteoblast differentiation from mesenchymal
precursors are in competition during development [16,17] and
the factors that stimulate progression in one lineage are likely to
inhibit the commitment towards the other one.
A growing literature of humanmedial calcification in T2DM and
aging is suggesting that the VSMCs that predominate in these
lesions lose expression of calcification inhibitors, such as matrix
Gla protein (MGP), and begin to express chondrocyte markers such
as type II collagen [18]. Moreover, histological examination of
femoral arteries from two patients with long-term T2DM revealed
the presence of type II collagen in foci of cartilaginous metaplasia,
providing evidence for endochondral ossification [19]. In addition,
in low density lipoprotein receptor mutant (Ldlr/) mice, T2DM
accelerated cartilage formation and calcification in the aorta [20].
Several factors may be involved in VSMC differentiation into chon-
drocytes and calcification in patients with T2DM. Recent studies
indicated that vascular calcification is enhanced by hyperglycemia.
In agreement with this view, Chen et al. observed that exposing
bovine VSMCs to high levels of glucose resulted in higher Runx2
and osteocalcin expression, as well as stimulated alkaline phos-
phatase activity and mineralization capacity compared to cells
exposed to normal glucose levels [21]. In addition, in culture of
human aortic smooth muscle cell, glucose increased the expression
of Runx2 and bone morphogenetic protein-2 [22]. Further, in rat
VSMCs, high glucose medium increased alkaline phosphatase
activity, mineralization and osteocalcin expression [23,24].Table 1
Summary of primers used. Shown are the primer sequences (F: forward; R: reverse), annea
GenBank accession numbers (CASP1: caspase-1, COL2A1: collagen type II, a1 chain; IL
phosphoprotein P0; TNAP: tissue-non specific alkaline phosphatase; TXNIP: thioredoxin-i
Gene GenBank Ta (C)
hCASPl NM033292.3 60
hCOL2A1 BC007252.1 62
hIL1b NM000576.2 62
hIL6 NM000600.3 62
hOCN NM199173.4 57
hRPLP0 M17885.1 60
hRUNX2 NM001024630.3 60
hSOX9 NM000346.3 62
hTNAP NM000478.4 60
hTXNIP NM006472.4 62
mActin NM007393.3 62
mCol2A1 NM031163.3 60
mOcn NM001037939.2 60
mRunx2 NM009820.5 62
mSox9 NM011448.4 60
mTnap NM007431.3 60However, these studies didn’t indicate whether VSMCs undergo
osteoblast or chondrocyte differentiation.
Nowadays, it is acknowledged that T2DM is associated with an
inflammatory status with elevated levels of several pro-
inflammatory cytokines [25]. Glucose itself exerts pro-
inflammatory effects in a wide array of cells including VSMCs
[26,27]. Some of the cytokines activated by glucose are likely to
stimulate VSMCs to calcify since calcification is stimulated by
TNF-a in culture and since blockade of tnf-a with infliximab
reduced calcification by 30% in diabetic Ldlr/ mice [28]. In addi-
tion, IL-1b secretion is stimulated by hyperglycemia and has
became a therapeutic target in patients with T2DM [29,30].
Glucose may stimulate IL-1b secretion through different mecha-
nisms, but up-regulation of thioredoxin-interacting protein
(TXNIP) has been proposed as an important pathway [31]. Hence,
a role for IL-1b in vascular calcification may not be surprising.
In this context, the aim of this study was to investigate the
effects of glucose on VSMC trans-differentiation and calcification
and to explore a possible role of IL-1b during this process. Upon
characterizing the MOVAS model of VSMCs [32,33] as well as pri-
mary human VSMCs, we found that glucose stimulates chondro-
cyte trans-differentiation of VSMCs and calcification. This is
accompanied by increased IL-1b expression. We also show that
treating VSMCs with IL-1b can induce VSMC trans-differentiation
and calcification.
2. Materials and methods
2.1. Cell cultures
MOVAS cells (ATCC, Molsheim, France) were cultured in DMEM
medium (25 mM glucose) supplemented with 10% fetal calf serum
(FCS), penicillin (100 U/mL), streptomycin (100 lg/mL), 20 mMling temperatures (Ta), base pair (bp) lengths of the corresponding PCR products, and
-1b: interleukin-1b; IL-6: interleukin 6; OCN: osteocalcin; RPLP0: acidic ribosomal
nteracting protein).
Sequences Lengths (bp)
F: 50-CCGCAAGGTTCGATTTTCA-30
R: 50-ACTCTTTCAGTGGTGGGCATCT-30
66
F: 50-GGCAATAGCAGGTTCACGTACA-30
R: 50-CGATAACAGTCTTGCCCCACTT-30
79
F: 50-CTCGCCAGTGAAATGATGGCT-30
R: 50-GTCGGAGATTCGTAGCTGGAT-30
144
F: 50-CAAGCGCCTTCGGTCCAGTT-30
R: 50-GCTGAGATGCCGTCGAGGAT-30
181
F: 50-ATGAGAGCCCTCACACTCCTC-30
R: 50-GCCGTAGAAGCGCCGATAGGC-30
294
F: 5 0-CGACCTGGAAGTCCAACTAC-30
R: 5 0-AGCAACATGTCCCTGATCTC-30
289
F: 5 0-GCTGTTATGAAAAACCAAGT-30
R: 5 0-GGGAGGATTTGTGAAGAC-30
108
F: 5 0-ACGCCGAGCTCAGCAAGA-30
R: 5 0-CACGAAGGGCCGCTTCT-30
71
F: 50-CAAAGGCTTCTTCTTGCTGGT-30
R: 50-AAGGGCTTCTTGTCTGTGTC-30
258
F: 50-CAGCCAACAGGTGAGAATGA-30
R: 50-TTGAAGGATGTTCCCAGAGG-30
104
F: 50-AATTTCTGAATGGCCCAGGT-30
R: 50-GGTAAGGTGTGCACTTTTATTGG-30
156
F: 50-CAGGTGAACCTGGACGAGAG-30
R: 50-ACCACGATCTCCCTTGACTC-30
86
F: 50-AAGCAGGAGGGCAATAAGGT-30
R: 50-CGTTTGTAGGCGGTCTTCA-30
364
F: 50-GCCGGGAATGATGAGAACTA-30
R: 50-GGACCGTCCACTGTCACTTT-30
200
F: 50-GTACCCGCATCTGCACAAC-30
R: 50-CTCCTCCACGAAGGGTCTCT-30
94
F: 50-CAAAGGCTTCTTCTTGCTGGT-30
R: 50-AAGGGCTTCTTGTCCGTGTC-30
258
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humidified atmosphere with 5% CO2 in air. To investigate the effect
of glucose on cell calcification, MOVAS cells were seeded at a den-
sity of 2000 cells per cm2 and cultured in DMEM (5.5 mM glucose)
supplemented as described above 2–3 days before treatment. Cells
were then treated at confluence with 10 mM b-GP and 50 lg/mL
ascorbate in DMEM containing 5.5 or 25 mM glucose. Human
VMSCs were purchased from Lonza (Walkersville, USA; reference
CC-2571/7F3110). They were cultured in routine in DMEMmedium
(25 mM glucose) supplemented with 5% FCS, penicillin (100 U/mL),
streptomycin (100 lg/mL), rhEGF (0.5 ng/mL), rhFGF-2 (2 ng/mL),
20 mM HEPES, and 2 mM L-glutamine. As for MOVAS cells, human
VSMC were treated at confluence with DMEM (5.5 or 25 mM glu-
cose) with 108 M 1,25(OH)2VD3, 10 mM b-GP and 50 lg/mL ascor-
bate. Media were replaced with fresh agents every 2–3 days.
2.2. Cell treatments
To determine the effect of IL-1b on TNAP activity, after reaching
confluence, human VSMC were treated with IL-1b (RD Systems,
0.1 ng/mL) for 7 days in DMEM (5.5 or 25 mM glucose) with
108 M 1,25(OH)2VD3, 10 mM b-GP and 50 lg/mL ascorbate. To
investigate gene expression, after reaching confluence, human
VSMC were differentiated for 3–4 days in DMEM (5.5 or 25 mMA B
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5 day 7
day14
day 21
A
liz
ar
in
 r
ed
 st
ai
n 
(5
70
 n
m
) 
C 
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
4,0 day 7
day 14
day 21
A
liz
ar
in
 r
ed
 st
ai
n 
(5
70
 n
m
) 
*** 
*** 
*** 
As
Gl
Ascorbate/ -GP       -                    +                    -                    + 
Glucose (mM)        5.5                 5.5                 25                  25           
Ascorbate/ -GP        -                    -     
Levamisole (μM)      0                 100   
Gluc
Fig. 1. Effects of high glucose concentration on TNAP activity and mineralization in MO
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treatment, followed by stain extraction with cetyl pyridinium and measurement of abs
21 days of treatment (n = 3, means ± SEM); (C) Alizarin red staining quantification after 7
glucose (25 mM) medium. * indicates a statistical difference with P < 0.05; ** indicates a sglucose) with 108 M 1,25(OH)2VD3, 10 mM b-GP and 50 lg/mL
ascorbic acid, then treated with IL-1b (0.1 ng/mL) for 2 days.
2.3. RNA extraction, reverse transcription and polymerase chain
reaction (RT-PCR)
Total RNA fromMOVAS cells was extracted using Trizol reagent.
Contaminating DNA was removed in a 20 min digestion at 37 C
with DNase I. 6 lg of each RNA sample were used for RT performed
under standard conditions with Superscript II reverse transcriptase
and random hexamer primers (Invitrogen, Cergy Pontoise, France).
The reaction was carried out at 42 C for 30 min and stopped with
incubation at 99 C for 5 min. Total RNA from hVSMC cells was
extracted using the NucleoSpin RNA II kit (Macherey–Nagel).
Quantitative PCR was performed using a LightCycler system
(Roche Diagnostics, Meylan, France). The primer sequences and
PCR conditions are given in Table 1. For MOVAS cells and human
VSMCs, all samples were quantified in triplicate and results are
shown as the mean of three different culture experiments.
Relative quantification analyses were performed by RelQuant
LightCycler software 4.1 (Roche Diagnostics, Meylan, France). The
calculated values of target gene expression were normalized to
that of actin, for MOVAS, or RPLP0 for hVSMCs used as internal
controls.0
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For the determination of TNAP activity using p-nitrophenyl
phosphate as the substrate [34], cells were harvested in 0.2%
Nonidet P-40 and disrupted by sonication. TNAP activity is
expressed as nmol of p-nitrophenol formed/min/mg of protein.
Calcium deposition was determined using 2% Alizarin Red staining
at pH 4.2 for 10 min, after quantification at 570 nm by extracting
the stain with 100 mM cetylpyridinium chloride for 2 h [35]. For
Alcian Blue staining, cells were rinsed with PBS followed by fixa-
tion in methanol at 20 C for 5 min. Staining was performed with
0.1% Alcian blue solution in HCl 0.1 M overnight at room tempera-
ture. For quantification, the bound staining was extracted after
extensive washing with guanidine HCl 6 M for 8 h, and the absor-
bance was measured at 620 nm.A 
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IL-1b concentration was determined in culture supernatants
using Enzo Lifesciences’ ELISA kit. Human VSMC were treated at
confluence with DMEM (5.5 or 25 mM glucose) with
108 M 1,25(OH)2VD3, 10 mM b-GP and 50 lg/mL ascorbate, in the
presence of 1 lg/mL of LPS (O55B5) or 50 ng/mL TNF-a.
2.6. Statistical analysis
All experiments were performed in triplicates and repeated at
least 3 times. Results were expressed as mean ± the standard error
of the mean (SEM). For statistical analysis, data were analyzed
between two groups by the non-parametric Mann–Whitney test,
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ered significant * when P < 0.05; ** when P < 0.01, *** when
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3.1. High glucose levels stimulate chondrocyte trans-differentiation of
mouse and human VSMCs
We first analyzed the effects of glucose on calcium deposition in
MOVAS cells. As previously reported [32], alizarin red staining
revealed that MOVAS cells deposited calcium only when cultured
in presence of ascorbate and b-GP (Fig. 1A). Quantification of cal-
cium deposition indicated that calcification was induced by ascor-
bate and b-GP between days 14 and 21 when glucose was provided
at normal levels (Fig. 1A). Interestingly, increasing the glucose
amount significantly increased this mineralization (Fig. 1A).
Aware that mineralization relies on the activity of TNAP in bone
[36] and VSMCs [37], we explored the effects of glucose on TNAP.
As shown in Fig. 1B, TNAP activity, in cells growing in the presence
of normal glucose supply, moderately increased from day 7 to day
21, where ascorbate/b-GP amplified this increase. Importantly,
ascorbate/b-GP-mediated increase of TNAP activity was clearly
amplified by increasing glucose levels (Fig. 1B). Observing that
the TNAP inhibitor, levamisole, completely abolished calcium
accumulation in culture supports further that this stimulation of
TNAP activity was involved in the increase in mineralization by
glucose itself (Fig. 1C). These observations confirmed that MOVAS
represents a convenient cell line to study vascular calcification
[32,33].
Since vascular calcification in patients with T2DM seems to pro-
ceed through a process similar to endochondral ossification
[18,19], we next sought to investigate the expression profile of sev-
eral chondrocyte markers after exposing cells to normal or high
glucose levels. Using real-time PCR, we show that increasing glu-
cose levels did not affect levels of the transcription factor Sox9,
but significantly induced levels of its transcriptional target type II
collagen (2.6-fold) (Fig. 2A). In addition, glucose increased the
deposition of sulfated GAGs by MOVAS (Fig. 2B). In a second step,
we assessed the mRNA levels of different markers of chondrocyte
hypertrophic differentiation. Although the mRNA levels of the
transcription factor Runx2 were unaltered after glucose treatment,
the levels of hypertrophic markers Tnap and osteocalcin were sig-
nificantly higher than those in normal glucose conditions
(Fig. 2C). Altogether, these data indicate that high glucose levels
accelerate the trans-differentiation of MOVAS VSMCs into
chondrocyte-like cells. To strengthen these results, we treated
human primary VSMCs with high glucose concentration. As shown
in Fig. 3, glucose led to the increased expressions of SOX9 and type
II collagen (Fig. 3A). Moreover, our results revealed a 2.1- and 1.5-
fold increase of the mRNA levels of the hypertrophic markers TNAP
and osteocalcin (Fig. 3B and C). Moreover, the increase in TNAP tran-
scripts was associated with an increase in TNAP activity (Fig. 3C).
These results therefore demonstrated that culturing mouse and
human VSMCs in high glucose levels accelerated their chondrocyte
trans-differentiation.3.2. IL-1b may contribute to the trans-differentiation of VSMC in
response to glucose
Observing that high glucose levels can stimulate calcification
and aware that IL-1b is a highly important cytokine activated by
glucose, we hypothesized that IL-1b could relay the effects of glu-
cose on vascular calcification. To address this proposal, we firstchecked if IL-1bmimics glucose effects in human VSMCs. As shown
in Fig. 4A, treating human VSMCs with IL-1b at 0.1 ng/mL for
2 days increased the mRNA levels of the transcription factors
SOX9 and RUNX2 (1.59-fold and 1.89-fold respectively).
Moreover, IL-1b stimulated the mRNA levels of TNAP and signifi-
cantly increased TNAP activity (Fig. 4B). In a second step, we
checked if glucose stimulates IL-1b expression and secretion.
Culturing human VSMCs in presence of ascorbate and b-GP for
3 days significantly increased the mRNA levels of IL-1b (3-fold),
and of one of its transcriptional targets IL-6 (by 9.5-fold).
Observing that high glucose levels had no additional effect on IL-
1b levels (Fig. 5A) may be explained by the fact that glucose acti-
vates IL-1b at the protein and not transcription level [31]. Indeed,
secretion of IL-1b is induced by its proteolytic cleavage by
caspase-1 under the control of the NLRP3 inflammasome, which
is activated by glucose through TXNIP [31]. Interestingly, it was
recently shown that activation of NLRP3 inflammasome is required
for VSMCs calcification [38]. In order to investigate the effect of
high glucose on NLRP3 inflammasome during the trans-
differentiation of human VSMC, cells were cultured in media con-
taining either normal or high glucose concentrations for 3 days,
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Interestingly, we observed that high glucose levels modestly
increased the levels of caspase-1 (by 2.6-fold) but strongly those
of TXNIP (by 50-fold) (Fig. 5B). Since hyperglycaemia activates IL-
1b through TXNIP transcription [31], our results suggest that IL-
1b was activated by high glucose levels in VSMCs, and was
involved in glucose-stimulated calcification.
4. Discussion
The mechanisms underlying the molecular pathogenesis of vas-
cular calcification in T2DM are extremely complex and are influ-
enced by the interactions between inflammatory factors, lipids
and oxidative stress. Several studies have suggested that vascular
calcification is enhanced by hyperglycaemia but the mechanisms
are poorly understood [18,19]. Collectively, our results suggest that
glucose itself stimulates cartilage formation in arteries. A major
output of this report is the different evidences suggesting that glu-
cose stimulates chondrocyte differentiation of mouse MOVAS cells
and human VSMCs. This is supported by the increase of type II col-
lagen expression and deposition of sulfated GAGs, two markers
that are not shared by osteoblasts. Chondrocyte commitment
was likely followed by chondrocyte hypertrophic differentiation,
attested by increased TNAP activity, mineralization and osteocalcin
levels. Importantly, in MOVAS, early chondrocyte markers were
increased after 14 days (sulfated GAGs, type II collagen), whereas
hypertrophic markers rose up only after 21 days (TNAP, calcium
deposition, osteocalcin expression), suggesting that these markers
were expressed by hypertrophic chondrocytes and not by osteo-
blasts differentiating besides chondrocytes in our cultures.
The fact that the mRNA levels of Sox9 and Runx2 transcription
factors didn’t vary in MOVAS cells suggests that in these VSMCs,
their activity rather than their expression, was stimulated by glu-
cose. On the other hand, levels of both SOX9 and RUNX2 were up-
regulated by glucose in human VSMCs, and in general, our data
point a greater responsiveness of human VSMCs, with strongest
increases and earlier effects (day 7 in human VSMCs versus day
14 or 21 in mouse VSMCs). It is difficult to determine possible rea-
sons for this discrepancy, due to use of an established mouse cell
line or of human primary cells. Nevertheless, the fact that glucose
stimulates chondrocyte differentiation in both mouse and human
VSMCs appears convincing, and can help to explain why a process
more similar to endochondral ossification rather than endomem-
branous ossification takes place in the arteries of patients with
T2DM [18,19].
Several important reports indicate that at least part of the glu-
cotoxicity observed in diabetic patients relies on the activation of
inflammatory cytokines. TNF-a has been shown to stimulate calci-
fication in culture of VSMCs [39–41], and in diabetic Ldlr/ mice,
blockade of Tnf-a reduced calcification by 30% [28]. In these dia-
betic mice, Tnf-a blockade didn’t decrease hyperglycaemia, sug-
gesting that TNF-a acts downstream of glucose. On the other
hand, the fact that only 30% of calcium deposition was prevented
suggests that other factors are involved in the pro-calcifying effects
of glucose.
Glucose stimulates IL-1b secretion through the sequential acti-
vation of TXNIP, NLRP3 and caspase-1 [31], and IL-1b has emerged
as the main inflammatory cytokine to target in patients with T2DM
[30]. Interestingly, it was recently shown that the NLRP3 inflam-
masome is required for mineralization in culture of rat VSMCs
[38]. In this latter report, IL-1bwas secreted throughout the miner-
alization process and NLRP3 silencing resulted in decreased IL-1b
secretion and calcification [38]. Using human cells, we confirmed
that culture of VSMCs in presence of ascorbic acid and b-GP signif-
icantly increased the levels of IL-1b, together with those of TXNIPand caspase-1. Moreover, the expression of TXNIP and caspase-1
was further increased by glucose, suggesting that glucose strength-
ens the secretion of IL-1b induced by mineralizing conditions.
However, we could not detect significant levels of secreted IL-1b
(above 1 pg/mL) by human VSMCs, in response to glucose or even
TNF-a, suggesting that levels of IL-1b secreted by human VSMCs
are quite low. Moreover, inhibition of IL-1b binding to its receptors
with IL-1 receptor antagonist (IL-1Ra, 50 ng/mL) only provided
inconsistent inhibition of glucose effects on the levels of SOX9,
RUNX2 and TNAP. These inconsistent effects may be due to several
causes. For instance, glucose activates the inflammasome to induce
the secretion of not only IL-1b, but also that of IL-18. Maybe IL-18
also impacts VSMC behavior. Alternatively, it may be possible that
in some experiments, IL-1Ra was not fully effective to prevent the
binding of IL-1b to its receptor. To overcome these problems, the
use of caspase-1 inhibitors, NLRP3 silencing, and cells from mice
deficient in IL-1 receptor will be useful approaches. Indeed, mice
deficient in NLRP3 for instance show improved glucose tolerance
and insulin sensitivity [31,42]. Whether absence of NLRP3 or
caspase-1 also impacts vascular calcification in diabetes therefore
warrants careful examination.
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